

02 Oct 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona's COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 September 2023, including: major Q4 catalysts; [Verona Pharma plc](#)'s COPD contender; [Alfasigma S.p.A.](#) acquires [Intercept Pharmaceuticals, Inc.](#); more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Biopharma's Must-Know Q4 Catalysts](#)" - Scrip, 26 Sep, 2023.)

(Also see "[What Verona Needs To Make COPD Drug Ensifentrine A Success](#)" - Scrip, 26 Sep, 2023.)

(Also see "[Italy's Alfasigma Comes Calling After Intercept's Cruel Summer](#)" - Scrip, 26 Sep, 2023.)

(Also see "[Two LEAPs Behind: Merck/Eisai Post Pair Of Failures Of Keytruda/Lenvima Combo](#)" - Scrip, 22 Sep, 2023.)

(Also see "[China's IPO Tightening Adds To Uncertainties Over Biotechs Going Public](#)" - Scrip, 28 Sep, 2023.)

[Click here to explore this interactive content online](#) 